Vijaya Diagnostic Centre Limited share price
NSE: VIJAYA · ISIN INE043W01024
Key numbers
- Market cap
- ₹ 15,590 Cr
- Current price
- ₹ 1,513.60
- 52-week high / low
- ₹ 1,594 / 848
- Stock P/E
- 83.3
- Book value
- ₹ 93.1
- Dividend yield
- 0.13%
- ROCE
- 21.1%
- ROE
- 19.7%
- Debt to equity
- 0.44
- Sales growth (3 yrs)
- 21.0%
- Profit growth (3 yrs)
- 26.9%
- 1-year return
- 44.2%
About Vijaya Diagnostic Centre Limited
Vijaya Diagnostic Centre Limited provides diagnostic services for patients in India. The company offers laboratory services, including clinical pathology, microbiology, haematology, serology, histopathology, cytogenetics, biochemistry, and molecular diagnostics; radiology services, such as CT scan, magnetic resonance imaging (MRI) scan, ultrasound, X-ray, cardiology, and gastroenterology; and advance radiology service comprising nuclear medicine, positron emission tomography CT, and MRI-3T services. It also provides health checkups and home sample collection services, as well as test services. Vijaya Diagnostic Centre Limited was founded in 1981 and is based in Hyderabad, India.
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 173 | 188 | 205 | 219 | 231 |
| Operating profit | 69 | 74 | 86 | 96 | 99 |
| Net profit | 35 | 39 | 43 | 48 | 53 |
| EPS (₹) | 3.39 | 3.76 | 4.20 | 4.66 | 5.16 |
Investor presentation summary (2026-09-11)
AI summary of the presentation · tone: Positive · source document
Key numbers
- Healthy Financials with ~80% Gross Margin and ~21% EBITDA margin (1)
Guidance & outlook
- Q2 & H1 FY25 Earnings Presentation, November 07, 2024
- FY26 Financial Performance
Growth & demand
- Company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and
Margins & costs
- EBITDA (2) | EBITDA Margin %
- 2. IND AS EBITDA1. Excluding OPD consultation fee
Capex & expansion
- Requirements) Regulations, 2015 – Strategic Acquisition / Execution of Business Transfer
- the approval/execution of the Business Transfer Agreement (BTA) for the 100% acquisition of the
Peers in Diagnostics & Research
Data for information only, not investment advice. Prices end of day.